SCHEMBL6476575

SCHEMBL6476575

Cc1c(=O)c(Cc2ccc(F)c(F)c2)cn2nc(C(=O)O)[nH]c12

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 2/20 0.40
KDM5B Q9UGL1 2/20 0.40
P2RY14 Q15391 1/20 0.36
RXRA P19793 1/20 0.34
MPO P05164 1/20 0.33
LDHA P00338 1/20 0.33
LDHB P07195 1/20 0.33
PDE2A O00408 1/20 0.33
P2RX7 Q99572 3/20 0.32
KDM4C Q9H3R0 1/20 0.31
CACNA1H O95180 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.31
ALDH1A1 P00352 1/20 0.31
TSHR P16473 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
EGLN1 Q9GZT9 1/20 0.31
PARP1 P09874 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6813649 0.91 KDM5A (0.36) KDM5AKDM5BP2RY14MPOLDHA
SCHEMBL6813645 0.90 FYN (0.36) KDM5AKDM5BP2RY14MPOLDHA
SCHEMBL6478088 0.86 PTGER4 (0.41) P2RX7CACNA1HALDH1A1
SCHEMBL6813648 0.83 NAMPT (0.39) PDE2ACACNA1HALDH1A1L3MBTL1
SCHEMBL6489375 0.79 GRM4 (0.33) KDM5AKDM5BMPOP2RX7
SCHEMBL6289368 0.79 KDM5A (0.38) KDM5AKDM5BP2RY14RXRAMPO
SCHEMBL6490897 0.77 KDM5A (0.38) KDM5AKDM5BP2RY14RXRAMPO
SCHEMBL6485426 0.77 P2RY14 (0.36) KDM5AKDM5BP2RY14RXRAMPO
SCHEMBL6289395 0.73 KDM5A (0.40) KDM5AKDM5BP2RY14RXRAMPO
SCHEMBL6476888 0.70 RXRA (0.35) KDM5AKDM5BP2RY14RXRALDHA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US claimed
US-6897223-B2 Pyridine fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-05-24 US disclosed
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US disclosed
WO-2004014908-A1 HETEROBICYLCIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 KDM5A 555/4885KDM5B 573/4885P2RY14 3000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.